View Post

Clinical Challenges: ADCs and Triple-Negative Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: The development of antibody drug conjugates adds a much needed option for women with TNBC Triple-negative breast cancer (TNBC) — i.e., breast cancer that does not express estrogen, progesterone, or HER2 receptors — comprises approximately 10%-20% of all breast cancers and represents “an unmet need in the field of breast oncology,” said Aditya Bardia, MD, …